XERS · Xeris Biopharma Holdings

The thesis

Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over the next three months. The reason is Recorlev, the company's Cushing's syndrome drug: its sales rose 93% to $71.5 million in the third quarter, and on 5 November 2026 management raised 2026 revenue guidance to $395–405 million. The first test comes in early January 2027, when the company has in the past given preliminary fourth-quarter revenue. It did so on 8 January 2026 for 2025, ahead of its full-year report on 2 March 2026.

The shares closed at $16.66 on 13 November 2026, a new closing high and 1.3% below the 52-week intraday high of $16.88 set on 12 November 2026. They are up 95.5% over three months from the $8.52 close on 17 August 2026. At that price the market already pays 8.4 times sales for the business. The close sits above Piper Sandler's $12 target, just under the $18 targets from HC Wainwright (6 November 2026) and Barclays (11 November 2026), and below Oppenheimer's $21 (6 November 2026).

The rating is Medium because the gain rests on reported results, a guidance raise and four analyst target increases since the report. Three things hold the odds below High. One drug carries the growth. Insiders keep selling under pre-arranged plans. The valuation now leaves little room for a soft fourth quarter.

Bullish and bearish views on Xeris Biopharma Holdings, Inc.

The bull case on Xeris Biopharma Holdings, Inc. (XERS), in brief: Recorlev growth sped up. The bear case: one drug carries the growth.

Bull case

• Recorlev growth sped up. Recorlev net revenue was $71.5 million in the quarter ended 30 September 2026, up 93% from a year earlier, according to the 5 November 2026 earnings release. On the 5 November 2026 call, management credited the expanded sales team with record referrals and new patient starts.
• Guidance rose above the estimate. On 5 November 2026 the company raised 2026 total revenue guidance to $395–405 million, from $385–390 million. Benzinga put the consensus estimate at $387.665 million when the report came out. The guide had started the year at $375–390 million on 2 March 2026.
• The quarter was profitable. Net income was $11.3 million, against $0.6 million a year earlier, according to the release. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose $13.3 million to $30.8 million. Filed figures show gross margin of 88.4% and operating margin of 15.8%, against 85.2% and 9.0% a year earlier.
• The long-range outlook moved up. On 5 November 2026 the company raised its 2030 revenue outlook to more than $1 billion, from about $750 million. It said Recorlev could reach nearly $1 billion in annual net revenue three to four years sooner than it had expected.
• Analysts raised targets after the report. Oppenheimer raised its target to $21 from $18 (Outperform) and HC Wainwright to $18 from $10 (Buy) on 6 November 2026. Barclays kept its Overweight rating and raised its target to $18 from $14 on 11 November 2026, according to Benzinga and Daily Political.
• The company has beaten its own numbers before. On 8 January 2026 Xeris said 2025 revenue would be about $292 million, above its $285–290 million guidance, and the 2 March 2026 report confirmed it.
• A buyer has shown interest. On 29 September 2026 Investing.com carried a Bloomberg report that H. Lundbeck was working with advisers on a possible acquisition, with talks described as preliminary. A Xeris spokeswoman said the company is not for sale.

Bear case

• One drug carries the growth. Recorlev was $71.5 million of $106.3 million in third-quarter net product revenue, according to the release. Gvoke fell 14% to $21.7 million, including a one-time $4 million adjustment. Keveyis rose 9% to $13.0 million.
• Costs are rising with sales. Selling, general and administrative expense rose 38% to $64.1 million in the third quarter, and 32% to $178.3 million over nine months, according to the release. Net income over the four quarters to 30 September 2026 was a loss of $6.5 million, according to filed figures.
• The price asks a lot. At the 13 November 2026 close the shares trade at 66.3 times operating profit and 62.4 times book value, on filed figures to 5 November 2026. Equity was $49 million at 30 September 2026.
• Generic challenges are pending. Torrent, Somerset, Sandoz, Zydus and Novitium have filed Paragraph IV challenges to Recorlev patents in the District of New Jersey, according to the third-quarter 10-Q. A bench trial is tentatively set for November 2028.
• One post-report target sits below the price. Piper Sandler raised its target to $12 from $8 on 6 November 2026 and kept a Neutral rating. The 13 November 2026 close of $16.66 is 39% above it.
• Insiders sell every month. SEC Form 4 filings show Kevin McCulloch sold 25,000 shares at $12.49 on 5 November 2026. On 2 November 2026 McCulloch sold 15,000, Beth Hecht 25,000 and Steven Pieper 5,000 shares at $10.23, after similar sales at $9.41 on 1 October 2026. All were made under Rule 10b5-1 plans, which are pre-arranged trading plans.
• Debt exceeds cash. Cash and short-term investments were $131 million and long-term debt $190 million at 30 September 2026, according to the 10-Q. The diluted share count rose 6.9% from a year earlier.

Price setup

The shares rose on the 5 November 2026 report in a session when the S&P 500 fell 3.3% and the Nasdaq 4.5%, according to Benzinga. Adjusted daily closes then show $15.20 on 6 November 2026, $15.86 on 9 November 2026 and $15.83 on 10 November 2026. New closing highs followed: $16.52 on 11 November 2026, $16.65 on 12 November 2026 and $16.66 on 13 November 2026.

As of the 13 November 2026 close, the 50-day moving average was $10.40 and the 200-day moving average $7.83. The shares have not pulled back since the report, so the gain has not been tested. The 50-day average sits close to where the shares traded before the report. The 52-week closing low was $5.29 on 24 March 2026, so the shares have roughly tripled from it.

A common market view is that a stock which nearly doubles in three months gives part of it back; tests on ten years of US stocks have found no reliable effect so far after rises of that size. The company's next scheduled events are the 17 November 2026 and 1 December 2026 conference fireside chats, the start of the Phase 3 trial of XP-8121 guided for year-end 2026, and the January preliminary revenue update the company gave in 2026.

Catalysts ahead

• 17 November 2026: Fireside chat at the Jefferies London Healthcare Conference, webcast live. It is the first scheduled public appearance since the 5 November 2026 report and may add detail on Recorlev referrals and spending.
• 1 December 2026: Fireside chat at the Piper Sandler Healthcare Conference in New York, webcast live. It gives management a second public setting to discuss Recorlev demand and 2027 spending, for which no guidance has been given.
• ~31 December 2026 (est.): Start of Cornerstone, the pivotal Phase 3 trial of XP-8121, guided for year-end 2026. It shows whether the next growth product enters late-stage testing on schedule, with topline results expected in late 2028.
• ~7 January 2027 (est.): Preliminary fourth-quarter and full-year 2026 revenue, following the 8 January 2026 precedent. It is the first read on whether Recorlev grows from the third quarter's $71.5 million and whether 2026 revenue lands inside the $395–405 million guidance.
• ~1 March 2027 (est.): Full fourth-quarter and full-year 2026 results with 2027 guidance. It sets the 2027 revenue and expense outlook, which shows whether growth near 2026's pace supports the current valuation.

What would change the view

A daily close below $10.46, the last close before the 5 November 2026 report, which would erase the post-earnings gain. The case would also break if fourth-quarter 2026 Recorlev revenue falls below the third quarter's $71.5 million, or 2026 total revenue comes in under $395 million.

The risks this note tracks, each with what would confirm it:

• Recorlev growth slows, leaving a company whose other two products contribute far less revenue. Confirmed by: fourth-quarter 2026 Recorlev revenue below the third quarter's $71.5 million, or 2026 total revenue under $395 million.
• 2027 guidance shows growth slowing sharply from 2026. Confirmed by: 2027 total revenue guidance below $475 million, under 20% growth on the 2026 guide of $395–405 million.
• Generic Recorlev reaches the market earlier than the company expects. Confirmed by: a court ruling or settlement in the Torrent/Somerset case in the District of New Jersey that allows generic levoketoconazole before 2032.
• Sales-force spending grows faster than revenue and earnings progress stalls. Confirmed by: adjusted EBITDA below the third quarter's $30.8 million, or 2027 expense guidance that outpaces revenue growth.
• The share price runs ahead of what analysts will underwrite. Confirmed by: a downgrade or target cut from Oppenheimer, HC Wainwright, Barclays or Piper Sandler, or insider sales stepping up beyond the recurring 10b5-1 schedule.
• The balance sheet needs new capital while debt exceeds cash. Confirmed by: New equity or convertible issuance, or a refinancing of the Hayfin loan due 5 March 2029 on worse terms.

What it trades with

Xeris is grouped with rare-disease drug makers such as Viridian Therapeutics (VRDN), Disc Medicine (IRON), Liquidia (LQDA) and Eton Pharmaceuticals (ETON). Its recent move has followed its own results more than the group or the market: it rose on 5 November 2026, a session in which the Nasdaq fell 4.5%, according to Benzinga. Unlike most of those peers, Xeris sells three approved products and reported a profit in the third quarter of 2026. Its shared exposures are mid-cap biotech sentiment and buyers' appetite for commercial-stage specialty drug makers, which the 29 September 2026 Lundbeck report put in focus. In Cushing's syndrome it competes with Corcept Therapeutics (CORT); in severe low blood sugar Gvoke competes with Amphastar's (AMPH) Baqsimi. If the peer group cools, the case rests on the Recorlev numbers.